MSD and Glenmark appeal pay-for-delay Zetia dispute
Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
19 March 2026 Although the court agreed that the tech giant misappropriated some of Masimo’s information related to pulse oximetry technology, Apple is not barred from using it, says a California judge.
17 March 2026 Janssen seeks injunctive relief after a forensic review uncovers mass downloads of trade secrets spanning oncology, neuroscience and immunology portfolios.
12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.
